



ASX Announcement

30 April 2018

Creso going for global expansion of anibidiol® product range following successful Swiss launch

Highlights:

- **Product expansion to penetrate the USD\$9.8 billion global companion animal market¹**
- **Positive customer feedback validates product and drives expansion globally**
- **First revenues already banked from sales of anibidiol® in Switzerland**

Creso Pharma Limited (ASX:CPH, the “Company” or “Creso”) has announced its engagement to expand the commercialization and distribution of anibidiol®, its CBD-based complimentary animal feed product following a successful launch in Switzerland.

The launch of anibidiol® in Switzerland in November 2017, with animal pharmaceutical giant Virbac Switzerland (“Virbac”), has generated early revenue for the company as well as very encouraging feedback for the product from customers and veterinarians. Creso are planning to commercialise the anibidiol® range across global markets throughout 2018 and beyond.

Rolf Heeb, Managing Director of Virbac Switzerland said, “We have been assured by the interest from vets that it was the right move and the right time to launch anibidiol®. There has been great interest from both vets and pet owners since its launch.”

This view has been further endorsed by Swiss vet Dr. Fabian Huwiler who added, “anibidiol® is a unique natural, organic and efficient feed supplement improving the quality of life of the pet and the pet owner; we were waiting for such a product”.

The global animal health market is valued at USD\$30 billion² and is projected to continue to grow rapidly. 41 percent of pet owners have considered or tried various alternative therapies including nutritional supplements (29 percent) and herbal remedies (7 percent)³.



“This promising start with anibidiol® in Switzerland sets a very sound foundation for Creso Pharma to progress into the international market arena”, said Creso Pharma Co-Founder and Chief Executive Officer Dr. Miri Halperin Wernli.

Creso is in the process to expand the anibidiol® product range through the development of additional products for companion animals with further launches with Virbac planned in 2018.



---ENDS---

Notes to Editors

1. Konzept Analytics: Global Animal Health Market Report: 2015 Edition). From the Cannpal prospectus
2. Vetnosis review 2016
3. Brown, L. P. (2001) Pet nutraceuticals: hype or wave of the future? Nutraceuticals World. January/February 2001 issue, pp. 34–41. Retrieved 31st July 2017 from http://www.nutraceuticalsworld.com/issues/2001-01/view_features/pet-nutraceuticals/

About Virbac

<https://corporate.virbac.com/home-en.html>
<https://www.virbac.ch/de/>

Virbac is a global pharmaceutical animal health company with a presence in over 100 countries and more than 4,800 employees and sales subsidiaries in 31 countries. Virbac ranks today as the 7th largest pharmaceutical veterinary company worldwide. Dedicated to animal health, Virbac offers veterinarians, farmers and pet owners in more than 100 countries a comprehensive and practical range of products and services. With these innovative solutions covering the majority of animal species and diseases, Virbac contributes, day after day, to shape the future of animal health.

For personal use only



About Creso Pharma

www.cresopharma.com

Creso Pharma brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. Creso develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

About anibidiol®

anibidiol® is a natural complementary feed for companion animals containing full spectrum hemp extract with cannabidiol (CBD), the non-psychoactive substance of the hemp plant, as well as hemp seed oil. This proprietary combination of CBD, the fatty acids Omega 3, Omega 6 and Omega 9, terpenes, flavonoids, and other active herbal ingredients have a complex interaction which enhances their overall health-promoting effect. The product promotes the well-being of the animal by supporting the immune and defence systems and contributing to balanced behaviour. anibidiol® is the first Swiss Agroscope conformed complementary feed for companion animals that contains natural hemp extract with CBD and is THC-free. The anibidiol® product range directly addresses the need for natural, non-pharmaceutical therapeutic approaches which are well tolerated by animals. The CBD contained in anibidiol® does not cause GI and dependency side effects and has a very good safety and tolerability profile.

For personal use only



Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation. The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.

Investor & Media Enquiries

Rob Gunning
Head of Investor Relations and Communications
Creso Pharma
TEL: +61 (0)457 000 857
E: rob.gunning@cresopharma.com

For personal use only